Douwe F Samplonius

List of Publications by Year
in descending order

16 papers	347 citations	10 h-index	16 g-index
16 all docs	16 docs citations	16 times ranked	695 citing authors

#	Article	IF	Citations
1	A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET. EJNMMI Radiopharmacy and Chemistry, 2022, 7, 3.	3.9	1
2	Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. Cancer Letters, 2021, 521, 109-118.	7.2	12
3	Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-18F-Fluoro-5α-Dihydrotestosterone. Journal of Nuclear Medicine, 2021, 62, 1140-1145.	5.0	7
4	Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis. OncoImmunology, 2021, 10, 2005344.	4.6	3
5	Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me"immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. OncoImmunology, 2020, 9, 1824323.	4.6	25
6	Modular Medical Imaging Agents Based on Azide–Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation of ^{18}F-Labeled PSMA-Tracers for Prostate Cancer Imaging. Chemistry - A European Journal, 2020, 26, 10871-10881.	3.3	13
7	Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. Journal of Investigative Dermatology, 2019, 139, 2343-2351.e3.	0.7	20
8	Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. Oncogene, 2019, 38, 1477-1488.	5.9	11
9	A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. OncoImmunology, 2018, 7, e1466016.	4.6	42
10	CD20-selective inhibition of CD47-SIRPα "don't eat me"signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. OncoImmunology, 2018, 7, e1386361.	4.6	58
11	A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. Scientific Reports, 2017, 7, 13301.	3.3	6
12	Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5. Journal of Investigative Dermatology, 2016, 136, 541-544.	0.7	18
13	Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. OncoImmunology, 2016, 5, e1202390.	4.6	35
14	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget, 2016, 7, 75130-75144.	1.8	64
15	CD20+T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. OncoImmunology, 2015, 4, e999536.	4.6	17
16	A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity. British Journal of Haematology, 2014, 164, 304-307.	2.5	15